Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK130 and AK112 in Advanced Biliary Tract Cancer
NCT06938321Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Apr 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lucorafusp alfa in biliary tract cancer (BTC) (2 arms), sponsored by Akeso, Inc. Primary endpoints: Number of subjects with dose limiting toxicities at 3 weeks, Number of subjects with adverse events and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
lucorafusp alfa
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06938321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938321.